ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
ARS Pharmaceuticals (Nasdaq: SPRY) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, December 2-4, 2025.
Company executives Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will take part in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Management will hold one-on-one investor meetings. A live webcast of the fireside chat will be available on the company website and a replay will be archived for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SPRY gained 3.13%, reflecting a moderate positive market reaction. This price movement added approximately $28M to the company's valuation, bringing the market cap to $917M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SPRY showed a 5.14% gain while peers were mixed: ATAI +1.61%, CRMD +2.53%, XERS +1.01%, RAPP +0.28%, and MRVI -0.8%. With no peers in the momentum scanner and no same-day peer headlines, the move appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference participation | Neutral | +3.1% | Announcement of Piper Sandler healthcare conference fireside chat and investor meetings. |
| Nov 10 | Earnings results | Neutral | +0.3% | Q3 2025 financials and neffy commercial progress with higher revenue and losses. |
| Nov 04 | Access program launch | Positive | +1.0% | Launch of Get neffy on Us program to expand access to neffy. |
| Nov 03 | Scientific meeting data | Positive | -3.8% | Real-world neffy data presentations at ACAAI annual scientific meeting. |
| Nov 03 | Earnings call notice | Neutral | -3.8% | Scheduling of Q3 2025 conference call and webcast for investors. |
Recent news usually produced modest price moves largely aligned with the news tone, with one negative divergence on a scientific conference update.
Over the last month, ARS Pharmaceuticals has reported Q3 2025 financial results, launched the Get neffy on Us access program, and highlighted multiple neffy® data presentations at the ACAAI meeting. These updates, along with earnings-related webcasts and today’s Piper Sandler conference participation, show an active commercial and investor-relations push around neffy. Price reactions have mostly been modest and directionally consistent with generally constructive news flow, except for a negative reaction to scientific meeting disclosures.
Market Pulse Summary
This announcement highlights ARS Pharmaceuticals’ participation in the Piper Sandler 37th Annual Healthcare Conference, including a December 3 fireside chat at 2:30 pm ET and one-on-one investor meetings. It reinforces ongoing investor-relations efforts following recent commercial and financial updates. The archived webcast, available for 90 days, offers additional access for stakeholders tracking neffy®’s rollout and corporate strategy. Investors may watch for subsequent earnings reports, new clinical data, and regulatory developments to refine their view of the story.
Key Terms
anaphylaxis medical
webcast technical
AI-generated analysis. Not financial advice.
SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025, in New York.
Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Company management will also participate in one-on-one meetings with investors.
A live webcast of the fireside chat will be available here, and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668
FAQ
When will ARS Pharmaceuticals (SPRY) present at the Piper Sandler 37th Annual Healthcare Conference?
Who from ARS Pharmaceuticals (SPRY) will speak at the Piper Sandler conference?
How can investors watch ARS Pharmaceuticals' (SPRY) fireside chat on December 3, 2025?
Will ARS Pharmaceuticals (SPRY) hold meetings with investors at the conference?
Where will the ARS Pharmaceuticals (SPRY) webcast replay be accessible and for how long?
What time is the ARS Pharmaceuticals (SPRY) fireside chat with Piper Sandler on December 3, 2025?
